Whereas the World Well being Group has declared that COVID-19 is not a worldwide well being emergency,1 the continuing evolution of SARS-CoV-2 nonetheless poses a big risk to public well being.2 In China, following the large-scale BA.5/BF.7 outbreak in late 2022, the XBB.1.5 variant turned dominant by early 2023 and brought about a renewed wave of infections. In response, a trivalent (XBB.1.5/BA.5/Delta) XBB-containing recombinant protein (trivalent XBB.1.5) vaccine was accepted for emergency use in June 2023. Our earlier research demonstrated that the trivalent XBB.1.5 vaccine booster elicited strong neutralizing antibodies towards a number of variants by day 21.3 On this research, we carried out a 480-day longitudinal follow-up of members in the identical cohort. Detailed strategies for follow-up, pseudovirus neutralization assay, and statistical evaluation are supplied within the Supplementary Methods.
We first analyzed neutralizing antibody titers towards D614G, BA.5, XBB.1.5, JN.1, KP.2, KP.3, KP.3.1.1, and XEC in serum samples collected at 120, 300, and 480 days post-booster from the identical cohort (Fig. 1a). The numbers of obtainable samples at every time level had been 32, 29, 26, and 28, respectively. The geometric imply titers (GMTs) towards all of the examined variants subsequently decreased in contrast with the titers on day 21. GMTs towards D614G confirmed a 3.1-fold discount by day 120 (GMT 7804, 95% confidence interval [CI] 5655–10,770), a 4.0-fold discount by day 300 (GMT 5978, 95% CI 3757–9511), and a 7.0-fold discount by day 480 (GMT 3435, 95% CI 2377–4963). With respect to BA.5, the GMTs decreased 2.4-fold (GMT 6026, 95% CI 3547–10,238), 3.3-fold (GMT 4363, 95% CI 3336–5706), and 12.7-fold (GMT 1147, 95% CI 754–1747), respectively. In distinction, the GMTs towards XBB.1.5, JN.1, KP.2, and KP.3 decreased extra step by step, with cumulative reductions of 4.6-, 2.7-, 2.2-, and a couple of.3-fold, respectively, by day 480. Statistically important reductions in GMTs towards KP.2 and KP.3 had been initially noticed by day 480 (GMT 564, 95% CI 414–770; and GMT 411, 95% CI 300–562, respectively). Notably, neutralizing antibody titers towards KP.3.1.1 and XEC variants remained low in any respect time factors. The GMTs towards KP.3.1.1 had been 453 on day 21, 268 on day 120, 377 on day 300, and 307 on day 480. The corresponding GMTs for XEC had been 375, 200, 262, and 308. Importantly, apart from D614G, the neutralizing antibody titers towards all of the examined variants on day 480 remained increased than the pre-booster ranges.
Longitudinal dynamics and decay kinetics of neutralizing antibody titers as much as 480 days after trivalent XBB.1.5 vaccination. a Dynamics of the 50% neutralizing antibody titers (NT50) towards the indicated pseudoviruses at 21, 120, 300, and 480 days post-booster. Geometric imply titers (GMTs, daring strains) are offered with shaded 95% confidence intervals (CIs). The GMTs and seropositivity charges (%) indicated above every time level had been calculated utilizing all obtainable samples (n = 32 on day 21, n = 29 on day 120, n = 26 on day 300, and n = 28 on day 480). The dotted horizontal line signifies the assay restrict of detection (NT50 = 30). A two-tailed Friedman check with a false discovery fee for a number of comparisons was carried out; p < 0.05 was thought of statistically important. Solely important variations are indicated, with the fold change in GMT proven in parentheses. Statistical comparisons throughout time factors had been carried out for the 24 members who accomplished all 4 follow-up visits. b Decay kinetics of the NT50 towards the indicated pseudoviruses at 21 (n = 32), 120 (n = 29), 300 (n = 26), and 480 (n = 28) days post-booster had been analyzed utilizing the exponential decay mannequin (strong line; coloured band signifies 95% CI) and the power-law decay mannequin (dashed line; grey band signifies 95% CI). The higher-fitting mannequin and the distinction within the Akaike data criterion corrected for small pattern measurement (ΔAICc) are proven. The estimated decay fee and half-life (in days) are displayed
We additional assessed the breadth of neutralizing exercise towards all of the variants examined at every time level. At 21 days post-booster, all 32 serum samples offered detectable neutralizing antibody titers (titers > 30) towards D614G, BA.5, XBB.1.5, JN.1, KP.2, and KP.3, whereas the seropositivity charges towards KP.3.1.1 and XEC had been each 93.8%. By day 120, 29 obtainable samples remained 100% seropositive towards D614G, BA.5, XBB.1.5, JN.1, and KP.3; the seropositivity charges for KP.2, KP.3.1.1, and XEC had been 96.6%, 93.1%, and 89.7%, respectively. XEC confirmed the best immune-evasive capacity, with titers 1.3- to 39.0-fold decrease than these of the opposite variants examined. At days 300 (n = 26) and 480 (n = 28), all of the samples towards all of the variants examined remained 100% seropositive and the fold variations between XEC and the opposite variants decreased significantly, from 1.4–22.8 on day 300 to 1.0–11.2 on day 480 post-booster.
We subsequent fitted the neutralizing antibody decay by way of each exponential and power-law decay fashions (Fig. 1b). The very best match for neutralizing antibodies towards D614G, XBB.1.5, JN.1, and KP.2 was the power-law mannequin and the estimated half-lives of neutralizing antibodies after day 21 had been 385 days (95% CI, 342–449), 517 days (95% CI, 369–988), 1,320 days (95% CI, 713–5174), and a couple of,445 days (95% CI, 710–1,824,187), respectively. The very best match for neutralizing antibodies towards BA.5 was the exponential decay mannequin, with a half-life of 139 days (95% CI, 120–162). For KP.3, each fashions have equal explanatory energy. The estimated half-lives of the exponential and power-law fashions had been 383 days (95% CI, 245–901) and a couple of,208 days (95% CI, 713–306,119), respectively. The half-lives of neutralizing antibodies towards KP.3.1.1 and XEC weren’t estimated due to the persistent low titers over the research interval.
Lastly, we examined the antigenic relationships among the many variants over time utilizing antigenic cartography. The mixed map of all sera revealed that the JN.1, KP.2, and KP.3 variants had been grouped collectively and positioned nearer to XBB.1.5 than to D614G, whereas KP.3.1.1 and XEC fashioned a extra distant cluster. Time-point-dependent maps revealed a gradual shortening of antigenic distances from pre-booster to 480 days post-booster, which was seemingly pushed by affinity maturation and undetected pure infections. Earlier than the booster, the variants had been extensively distributed, with antigenic distances from D614G starting from 1.9 antigenic items (AUs) for BA.5 to six.7 AUs for XEC. By day 21 post-booster, each BA.5 and XBB.1.5 had been nearer to D614G, with distances of 1.0 AU and a couple of.4 AUs, respectively. JN.1, KP.2, and KP.3 remained at better distances (4.4–5.1 AUs), and KP.3.1.1 and XEC nonetheless confirmed the best separation (6.0–6.4 AUs), indicating restricted early cross-reactivity to those later sublineages. By day 120, all of the variants had been nearer to D614G, with BA.5 at 0.3 AUs and JN.1, KP.2, and KP.3 within the vary of three.4–3.5 AUs. This sample continued by way of day 300, along with the small rebound noticed with BA.5 and XBB.1.5. By day 480, distances decreased markedly, from 1.4 AUs for XBB.1.5 to three.6 AUs for KP.3.1.1 and XEC—an ~49% discount from the height for JN.1-related variants.
Total, on this 480-day longitudinal research of trivalent XBB.1.5 booster, neutralizing antibody responses remained sturdy towards XBB.1.5, JN.1, KP.2, and KP.3 however had been persistently low towards extra antigenically distant KP.3.1.1 and XEC variants. In comparison with KP.3, the S31del mutation in KP.3.1.1 and the T22N and F59S mutations in XEC confer enhanced immune evasion. Curiously, excessive preliminary titers (day 21 post-booster) towards D614G, BA.5, and XBB.1.5 had been related to brief half-lives, whereas low preliminary titers towards JN.1, KP.2, and KP.3 had been related to longer half-lives. This titer-dependent decay sample means that antibody decline slows as titers lower, partly explaining the lengthy half-lives for variants with low preliminary neutralization. Nevertheless, a number of limitations needs to be thought of. Though the cohort measurement was enough for longitudinal modeling, it could not totally seize population-level heterogeneity and a few lacking visits (2 misplaced, 2–4 lacking per time level), though the mixed-effects strategy minimizes bias from incomplete follow-up. Our evaluation centered on neutralizing antibodies, precluding the evaluation of reminiscence B-cell and T-cell responses, that are important for long-term safety.4,5 Importantly, a significant limitation of our research is that the sturdy neutralizing antibody response may very well be influenced by unreported symptomatic or asymptomatic infections, as we didn’t carry out energetic surveillance of infections through the research interval. Future research incorporating mobile immunity and systematic an infection surveillance shall be vital to refine and lengthen these conclusions. Total, from a humoral perspective, the findings present proof that booster intervals shouldn’t be shorter than 6–9 months when XBB-like viruses predominate, however underscore the necessity for well timed antigenic updates to counter extremely immune-evasive rising lineages.6,7
